DE69334343D1 - Adeno-assoziiertes Virus mit invertierten Terminalen 'Repeats' als Promoter - Google Patents

Adeno-assoziiertes Virus mit invertierten Terminalen 'Repeats' als Promoter

Info

Publication number
DE69334343D1
DE69334343D1 DE69334343T DE69334343T DE69334343D1 DE 69334343 D1 DE69334343 D1 DE 69334343D1 DE 69334343 T DE69334343 T DE 69334343T DE 69334343 T DE69334343 T DE 69334343T DE 69334343 D1 DE69334343 D1 DE 69334343D1
Authority
DE
Germany
Prior art keywords
vector
promoter
gene
associated virus
adeno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69334343T
Other languages
English (en)
Inventor
Barrier J Carter
Terrence Flotte
Sandra Afione
Rikki Solow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69334343D1 publication Critical patent/DE69334343D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
DE69334343T 1992-06-02 1993-06-02 Adeno-assoziiertes Virus mit invertierten Terminalen 'Repeats' als Promoter Expired - Lifetime DE69334343D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/891,962 US5587308A (en) 1992-06-02 1992-06-02 Modified adeno-associated virus vector capable of expression from a novel promoter

Publications (1)

Publication Number Publication Date
DE69334343D1 true DE69334343D1 (de) 2010-11-18

Family

ID=25399130

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69334343T Expired - Lifetime DE69334343D1 (de) 1992-06-02 1993-06-02 Adeno-assoziiertes Virus mit invertierten Terminalen 'Repeats' als Promoter
DE69331194T Expired - Lifetime DE69331194T2 (de) 1992-06-02 1993-06-02 Adeno assozierter virus mit umgekehrten terminal repeat sequenzen als promotor fur den in vivo transfer eines funktionellen cftr gens

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69331194T Expired - Lifetime DE69331194T2 (de) 1992-06-02 1993-06-02 Adeno assozierter virus mit umgekehrten terminal repeat sequenzen als promotor fur den in vivo transfer eines funktionellen cftr gens

Country Status (11)

Country Link
US (5) US5587308A (de)
EP (2) EP0644944B1 (de)
AT (2) ATE483817T1 (de)
AU (1) AU673367B2 (de)
CA (1) CA2136441C (de)
DE (2) DE69334343D1 (de)
DK (1) DK0644944T3 (de)
ES (1) ES2168096T3 (de)
HK (1) HK1014549A1 (de)
PT (1) PT644944E (de)
WO (1) WO1993024641A2 (de)

Families Citing this family (450)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587308A (en) * 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5869305A (en) * 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6686200B1 (en) * 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
US5834441A (en) * 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US6652850B1 (en) * 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
FR2716893B1 (fr) * 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.
CA2187626C (en) * 1994-04-13 2009-11-03 Michael G. Kaplitt Aav-mediated delivery of dna to cells of the nervous system
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US6342390B1 (en) 1994-11-23 2002-01-29 The United States Of America As Represented By The Secretary Of Health And Human Services Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
US6924128B2 (en) * 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US6383814B1 (en) * 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6110456A (en) * 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US5646034A (en) * 1995-06-07 1997-07-08 Mamounas; Michael Increasing rAAV titer
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
JPH11510046A (ja) * 1995-07-21 1999-09-07 ローヌ−プーラン ローラー ファーマシューティカルズ インコーポレイテッド アデノ関連ウイルスリポソーム及び樹状細胞をトランスフェクトして特異性免疫を刺激することにおけるそれらの使用
US6207457B1 (en) * 1995-09-08 2001-03-27 Avigen, Inc. Targeted nucleotide sequence delivery and integration system
US6086913A (en) * 1995-11-01 2000-07-11 University Of British Columbia Liposomal delivery of AAV vectors
CA2279673A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acids for therapeutic and diagnostic uses
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
DE19608753C1 (de) * 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6245735B1 (en) 1996-07-29 2001-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating pseudomonas infection
US5866552A (en) * 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
CA2265460A1 (en) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Aav4 vector and uses thereof
WO1998048005A1 (en) 1997-04-24 1998-10-29 University Of Washington Targeted gene modification by parvoviral vectors
US6156303A (en) * 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6346415B1 (en) 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
WO1999020773A2 (en) * 1997-10-21 1999-04-29 Targeted Genetics Corporation TRANSCRIPTIONALLY-ACTIVATED AAV INVERTED TERMINAL REPEATS (ITRs) FOR USE WITH RECOMBINANT AAV VECTORS
US6642051B1 (en) * 1997-10-21 2003-11-04 Targeted Genetics Corporation Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
EP1042494A1 (de) 1997-12-23 2000-10-11 Introgene B.V. Chimere rekombinante vektoren abgeleitet von adeno-assoziiertem virus und adenovirus für die chromosomale integration von fremd-dns in zielzellen
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
US6294379B1 (en) 1998-02-25 2001-09-25 The Regents Of The University Of California Efficient AAV vectors
EP1068296B1 (de) 1998-03-31 2011-08-10 Geron Corporation Zusammensetzungen zur auslösung einer immunantwort gegen ein telomerase antigen
CA2326327C (en) 1998-04-24 2009-06-16 University Of Florida Recombinant adeno-associated virus vector encoding alpha-1-antitrypsin serum protein
ATE309352T1 (de) 1998-05-06 2005-11-15 Vlaams Interuniv Inst Biotech Inhibitoren der nf-kb aktivierung
US6146874A (en) * 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
US6984517B1 (en) 1998-05-28 2006-01-10 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector and uses thereof
ATE402254T1 (de) 1998-05-28 2008-08-15 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6395549B1 (en) 1998-10-22 2002-05-28 Medical College Of Georgia Research Institute, Inc. Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
US7129043B1 (en) 1998-10-22 2006-10-31 Duke University Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease
US6468793B1 (en) 1998-10-23 2002-10-22 Florida State University Research Foundation CFTR genes and proteins for cystic fibrosis gene therapy
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
JP2002538770A (ja) * 1998-11-10 2002-11-19 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ウイルスベクターとその製造及び投与の方法
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US6537540B1 (en) * 1999-05-28 2003-03-25 Targeted Genetics Corporation Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
AU5771500A (en) 1999-06-28 2001-01-31 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
PT1204739E (pt) * 1999-08-09 2008-11-17 Targeted Genetics Corp Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
CA2387484A1 (en) * 1999-10-12 2001-04-19 Haim Burstein Adeno-associated virus vectors encoding factor viii and methods of using the same
US7060497B2 (en) 2000-03-03 2006-06-13 The Board Of Trustees Of The Leland Stanford Junior University Adeno-associated viral vector-based methods and compositions for introducing an expression cassette into a cell
KR20020086508A (ko) 2000-02-08 2002-11-18 상가모 바이오사이언스 인코포레이티드 약물 발견용 세포
AU2001250922A1 (en) * 2000-03-22 2001-10-03 Board Of Trustees Of The University Of Arkansas Secreting products from skin by adeno-associated virus (aav) gene transfer
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
WO2002092619A2 (en) 2001-05-14 2002-11-21 The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
US7119172B2 (en) 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
WO2002094854A2 (en) 2001-05-21 2002-11-28 The Brigham And Women's Hospital, Inc. P.aeruginosa mucoid exopolysaccharide specific binding peptides
WO2002100317A2 (en) 2001-05-25 2002-12-19 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
AU2002350412B2 (en) 2001-06-22 2006-06-15 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Abin-mediated hepatitis protection
EP2266396A3 (de) 2001-09-24 2011-06-15 Sangamo BioSciences, Inc. Modulation von stammzellen mittels zinkfingerproteinen
CA2472927A1 (en) 2002-01-10 2003-07-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A novel splice variant of myd88 and uses thereof
WO2003077865A2 (en) 2002-03-15 2003-09-25 Baxter International Inc. Methods and compositions for directing cells to target organs
US6825263B2 (en) * 2002-04-08 2004-11-30 Dow Corning Corporation Curable coating compositions from emulsions of elastomeric polymers and polyurethane dispersions
EP1495121A2 (de) 2002-04-18 2005-01-12 Lynkeus Biotech GmbH Mitteln und verfahren zur spezifischen hemmung von genen in zellen und gewebe vom zns und/oder dem auge
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
AU2003291678B2 (en) 2002-11-01 2009-01-15 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
CN102304570B (zh) 2002-11-13 2015-01-21 托马斯杰斐逊大学 用于癌症诊断和治疗的组合物和方法
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
ATE477337T1 (de) 2003-01-16 2010-08-15 Univ Pennsylvania Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
WO2005017101A2 (en) 2003-05-19 2005-02-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Avian adenoassociated virus (aaav) and uses thereof
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP2927318B1 (de) 2003-08-08 2020-05-20 Sangamo Therapeutics, Inc. Verfahren und Zusammensetzungen für gezielte Spaltung und Rekombination
WO2005028630A2 (en) 2003-09-19 2005-03-31 Sangamo Biosciences, Inc. Engineered zinc finger proteins for regulation of gene expression
US8137960B2 (en) 2003-12-04 2012-03-20 The United States Of America As Represented By The Department Of Health And Human Services Bovine adeno-associated viral (BAAV) vector and uses thereof
WO2005078139A2 (en) 2004-02-09 2005-08-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
EP1735009A4 (de) 2004-03-12 2011-03-30 Alnylam Pharmaceuticals Inc Irna mittel targeting vegf
US7569362B2 (en) * 2004-03-15 2009-08-04 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
AU2005233583B2 (en) 2004-04-08 2011-02-03 Sangamo Therapeutics, Inc. Methods and compositions for modulating cardiac contractility
US20080131962A1 (en) 2006-05-25 2008-06-05 Sangamo Biosciences, Inc. Engineered cleavage half-domains
WO2006036465A2 (en) * 2004-09-03 2006-04-06 University Of Florida Compositions and methods for treating cystic fibrosis
CA2579677A1 (en) 2004-09-16 2006-03-30 Sangamo Biosciences, Inc. Compositions and methods for protein production
AU2005316476A1 (en) * 2004-12-15 2006-06-22 University Of Florida Research Foundation, Inc. Chimeric vectors
ATE553122T1 (de) 2005-02-28 2012-04-15 Sangamo Biosciences Inc Antiangiogene methoden und zusammensetzungen
BRPI0610075B8 (pt) 2005-04-22 2021-06-22 Evonik Degussa Gmbh estruturas de poliméro de absorção de água, seus usos, processos para tratamento da superfície das mesmas, compostos, processos para produção dos mesmos, produtos compreendendo as estruturas poliméricas e usos de combinações de óxidos de metal e sais de metal de cátion de metal bivalente ou trivalente
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
KR101419729B1 (ko) 2005-07-26 2014-07-17 상가모 바이오사이언스 인코포레이티드 외래 핵산 서열의 표적화된 통합 및 발현
EP1937280B1 (de) 2005-09-12 2014-08-27 The Ohio State University Research Foundation Zusammensetzungen zur Therapie von Bcl2-assoziierten Tumoren
EP2345417A1 (de) 2005-12-22 2011-07-20 Vib Vzw Mittel und Verfahren zur Interferenz mit Proteinen
US8669418B2 (en) 2005-12-22 2014-03-11 Vib Vzw Means and methods for mediating protein interference
CA2634286A1 (en) 2005-12-22 2007-08-09 Samuel Jotham Reich Compositions and methods for regulating complement system
ES2429404T3 (es) 2006-01-05 2013-11-14 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico y el pronóstico del cáncer de pulmón
EP2591794A1 (de) 2006-01-05 2013-05-15 The Ohio State University Research Foundation Anomalien bei Mikro-RNA-Expressionen in endokrinen und azinösen Pankreastumoren
ES2536423T3 (es) 2006-01-05 2015-05-25 The Ohio State University Research Foundation Métodos basados en microARN para el diagnóstico de cáncer de próstata
EP2522746B1 (de) 2006-03-02 2014-11-12 The Ohio State University Research Foundation Mikro-RNA-Expressionsprofil im Zusammenhang mit Bauchspeicheldrüsenkrebs
EP1996731A2 (de) 2006-03-20 2008-12-03 The Ohio State University Research Foundation Mikrorna-fingerabdrücke während humaner megakaryozytopoiese
KR101547579B1 (ko) 2006-03-31 2015-08-27 알닐람 파마슈티칼스 인코포레이티드 Ｅｇ5 유전자의 발현을 억제하는 이본쇄 리보핵산
US7691824B2 (en) 2006-04-28 2010-04-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the JC virus
WO2007134161A2 (en) 2006-05-11 2007-11-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the pcsk9 gene
CN101489566B (zh) 2006-05-19 2012-04-18 阿尔尼拉姆医药品有限公司 Aha基因的RNAi调控及其治疗性应用
CA2653451C (en) 2006-05-22 2015-12-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of ikk-b gene
US8598333B2 (en) 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
ES2390499T3 (es) 2006-06-12 2012-11-13 Opko Pharmaceuticals, Llc Composiciones y métodos para la inhibición de la angiogénesis por sirna
AU2007272947B2 (en) 2006-07-13 2013-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Micro-RNA-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
AU2007277392A1 (en) * 2006-07-25 2008-01-31 Celladon Corporation Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
US7872118B2 (en) 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
CA2663581C (en) 2006-09-21 2016-03-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the hamp gene
US8841436B2 (en) 2007-03-15 2014-09-23 University Hospitals Cleveland Medical Center Screening, diagnosing, treating and prognosis of pathophysiologic status by RNA regulation
PE20090064A1 (es) 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
CN101678082B (zh) 2007-03-26 2013-06-19 再生医药有限公司 使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
JP5350360B2 (ja) 2007-03-29 2013-11-27 アルナイラム ファーマシューティカルズ， インコーポレイテッド エボラ由来の遺伝子の発現を阻害するための組成物および方法
BRPI0814189A2 (pt) 2007-07-05 2015-03-03 Novartis Ag Ácido ribonucleico de filamento duplo, composição farmacêutica e seus usos, método para inibir a expressão de fosfatidilinositol 4-cinase, vetor e uso de um composto que seletivamente inibe a atividade da fosfatidilinositol 4-cinase.
CN101883850B (zh) 2007-07-12 2014-11-12 桑格摩生物科学股份有限公司 用于失活α-1,6岩藻糖基转移酶(FUT8)基因表达的方法和组合物
WO2009012263A2 (en) 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
CN101809169B (zh) 2007-07-31 2013-07-17 俄亥俄州立大学研究基金会 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
EP2650383A1 (de) 2007-08-03 2013-10-16 The Ohio State University Research Foundation Ultrakonservierte Bereiche zur Codierung von ncRNA
CA2926831A1 (en) 2007-08-22 2009-02-26 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
JP5401460B2 (ja) 2007-09-06 2014-01-29 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション ヒト卵巣癌中のマイクロｒｎａシグネチャー
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
JP5723156B2 (ja) 2007-10-11 2015-05-27 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 食道腺癌の診断及び治療のための方法及び組成物
EP2612868B1 (de) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunsuppressive Polypeptide und Nucleinsäuren
JP5530933B2 (ja) 2007-12-10 2014-06-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド 第ｖｉｉ因子遺伝子発現阻害のための組成物及び方法
AU2008350903B2 (en) 2008-02-19 2015-04-02 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
JP2011518117A (ja) 2008-03-05 2011-06-23 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｅｇ５およびＶＥＧＦ遺伝子の発現を阻害するための組成物および方法
JP5763530B2 (ja) 2008-06-10 2015-08-12 サンガモ バイオサイエンシーズ， インコーポレイテッド Ｂａｘ−およびＢａｋ−欠損細胞株の生成のための方法および組成物
KR20160015400A (ko) 2008-08-22 2016-02-12 상가모 바이오사이언스 인코포레이티드 표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물
WO2010028054A1 (en) 2008-09-02 2010-03-11 Alnylam Europe Ag. Compositions and methods for inhibiting expression of mutant egfr gene
EP2334793B1 (de) 2008-09-25 2016-04-06 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der expression des serumamyloid-a-gens
EA029762B1 (ru) 2008-10-20 2018-05-31 Элнилэм Фармасьютикалз, Инк. Композиции и способы для ингибирования экспрессии транстиретина
CN105079781B (zh) 2008-11-30 2018-07-20 免疫桑特公司 用于治疗乳糜泻的组合物和方法
NZ593743A (en) 2008-12-04 2012-07-27 Opko Ophthalmics Llc Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
WO2010068816A1 (en) 2008-12-10 2010-06-17 Alnylam Pharmaceuticals, Inc. Gnaq targeted dsrna compositions and methods for inhibiting expression
CA2749965C (en) 2009-02-04 2018-09-11 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathies
ES2634118T3 (es) 2009-02-11 2017-09-26 The University Of North Carolina At Chapel Hill Vectores de virus modificados y métodos para fabricar y utilizar los mismos
WO2010099341A1 (en) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mig-12 gene
JP6032724B2 (ja) 2009-03-12 2016-11-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 脂質製剤組成物およびＥｇ５遺伝子とＶＥＧＦ遺伝子の発現を阻害する方法
CN102405280B (zh) 2009-03-20 2015-03-04 中胚层公司 重新设定的多能干细胞的制备
EP2419511B1 (de) 2009-04-09 2018-01-17 Sangamo Therapeutics, Inc. Gezielte integration in stammzellen
PT2424991T (pt) 2009-05-02 2018-10-19 Genzyme Corp Terapia génica para distúrbios neurodegenerativos
EP2451475A2 (de) 2009-07-06 2012-05-16 Novartis AG Selbstreplizierende rna-moleküle und ihre verwendung
CN105214080A (zh) 2009-07-15 2016-01-06 诺华股份有限公司 Rsv f蛋白组合物和其制作方法
EP2461819A4 (de) 2009-07-28 2013-07-31 Sangamo Biosciences Inc Verfahren und zusammensetzungen zur behandlung erblicher trinukleotiderkrankungen
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
EP2774935B8 (de) 2009-10-30 2017-06-21 NTF Therapeutics, Inc. Verbesserte Neurturinmoleküle
CN105031618A (zh) 2009-11-02 2015-11-11 加利福尼亚大学董事会 用于细胞因子递送的穹窿体复合物
US8551781B2 (en) 2009-11-19 2013-10-08 The Regents Of The University Of California Vault complexes for facilitating biomolecule delivery
RU2012127772A (ru) 2009-12-04 2014-01-10 ОПКО ОФТЭЛМИКС, ЭлЭлСи Композиции и способы для ингибирования vegf
JP6137596B2 (ja) 2010-02-08 2017-05-31 サンガモ セラピューティクス， インコーポレイテッド 遺伝子操作された切断ハーフドメイン
US9255259B2 (en) 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
AU2011235276B2 (en) 2010-03-29 2015-09-03 Alnylam Pharmaceuticals, Inc. SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
CN103025344B (zh) 2010-05-17 2016-06-29 桑格摩生物科学股份有限公司 新型dna-结合蛋白及其用途
EP2576579B1 (de) 2010-06-02 2018-08-08 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von leberfibrose
EA201390085A1 (ru) 2010-07-09 2013-06-28 Экселиксис, Инк. Композиции ингибиторов киназ для лечения рака
US9057057B2 (en) 2010-07-27 2015-06-16 The Johns Hopkins University Obligate heterodimer variants of foki cleavage domain
EP3118316A1 (de) 2010-09-02 2017-01-18 Université de Mons Zur behandlung von fazioskapulohumeraler muskeldystrophie nützliche wirkstoffe
EP3511420B1 (de) 2010-09-27 2021-04-07 Sangamo Therapeutics, Inc. Zusammensetzungen zur hemmung des eindringens von viren in zellen
AU2011316707A1 (en) 2010-10-11 2013-05-09 Novartis Ag Antigen delivery platforms
WO2012078967A2 (en) 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for increasing erythropoietin (epo) production
EP2648763A4 (de) 2010-12-10 2014-05-14 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
EP2667892B1 (de) 2011-01-26 2019-03-27 GlaxoSmithKline Biologicals SA Rsv-immunisierungstherapie
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
JP6108628B2 (ja) 2011-03-29 2017-04-05 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｔｍｐｒｓｓ６遺伝子の発現を阻害する組成物および方法
PT3275892T (pt) 2011-05-13 2020-04-08 Glaxosmithkline Biologicals Sa Antigénios f de rsv de pré-fusão
WO2012164058A1 (en) 2011-06-01 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for adjusting expression of mitochondrial genome by microrna
RU2631805C2 (ru) 2011-06-21 2017-09-26 Элнилэм Фармасьютикалз, Инк. Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
EP3388068A1 (de) 2011-06-21 2018-10-17 Alnylam Pharmaceuticals, Inc. Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
CN103890000B (zh) 2011-06-21 2017-09-01 阿尔尼拉姆医药品有限公司 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法
CA2839896A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
EP3366312A1 (de) 2011-06-23 2018-08-29 Alnylam Pharmaceuticals, Inc. Serpina 1 sirnas: materialzusammensetzungen und verfahren zur behandlung
AU2012284365B2 (en) 2011-07-15 2017-04-20 The General Hospital Corporation Methods of transcription activator like effector assembly
US20140328811A1 (en) 2011-08-01 2014-11-06 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
CN103917644A (zh) 2011-09-21 2014-07-09 桑格摩生物科学股份有限公司 调控转基因表达的方法和组合物
BR112014008694A2 (pt) 2011-10-11 2017-06-20 Novartis Ag moléculas de ácido nucleico policistrônico recombinante
EP2766385A2 (de) 2011-10-12 2014-08-20 Novartis AG Cmv-antigene und verwendungen davon
JP2014530612A (ja) 2011-10-14 2014-11-20 ジ・オハイオ・ステート・ユニバーシティ 卵巣がんに関する方法および材料
EP2771482A1 (de) 2011-10-27 2014-09-03 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren zur behandlung und diagnose von arteriosklerose
AU2012327236B2 (en) 2011-10-28 2016-11-10 University Of Florida Research Foundation, Inc. Chimeric promoter for cone photoreceptor targeted gene therapy
EP3311847A1 (de) 2012-02-16 2018-04-25 Atyr Pharma, Inc. Histidyl-trna-synthetasen zur behandlung von autoimmun- und entzündungserkrankungen
WO2013130824A1 (en) 2012-02-29 2013-09-06 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
WO2013152230A1 (en) 2012-04-04 2013-10-10 The Trustees Of Columbia University In The City Of New York Smooth muscle specific inhibition for anti-restenotic therapy
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9193971B2 (en) 2012-04-10 2015-11-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for the treatment of nonalcoholic steatohepatitis
WO2013153139A1 (en) 2012-04-11 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and diagnosis of acute leukemia
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
EP2869828B1 (de) 2012-07-09 2018-01-03 The Regents of The University of California Vault immuntherapie
DK2872625T3 (en) 2012-07-11 2017-02-06 Sangamo Biosciences Inc METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISEASES
JP6329537B2 (ja) 2012-07-11 2018-05-23 サンガモ セラピューティクス， インコーポレイテッド 生物学的薬剤の送達のための方法および組成物
SI2890780T1 (sl) 2012-08-29 2020-11-30 Sangamo Therapeutics, Inc. Postopki in sestavki za zdravljenje genetskega stanja
EP2906684B8 (de) 2012-10-10 2020-09-02 Sangamo Therapeutics, Inc. T-zell-modifizierende verbindungen und verwendungen davon
EP3789405A1 (de) 2012-10-12 2021-03-10 The General Hospital Corporation Transkriptionsaktivator-like-effektor-lysinspezifische demethylase-1 (lsd1)-fusionsproteine
EP3336187A1 (de) 2012-12-05 2018-06-20 Alnylam Pharmaceuticals, Inc. Pcsk9-irna-zusammensetzungen und verfahren zur verwendung davon
BR112015013311A2 (pt) 2012-12-07 2017-11-14 Haplomics Inc indução de tolerancia e reparação de mutação do fator 8
ES2576128T3 (es) 2012-12-12 2016-07-05 The Broad Institute, Inc. Modificación por tecnología genética y optimización de sistemas, métodos y composiciones para la manipulación de secuencias con dominios funcionales
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
KR20150105635A (ko) 2012-12-12 2015-09-17 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
AU2013359199C1 (en) 2012-12-12 2021-06-17 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
RU2701850C2 (ru) 2012-12-12 2019-10-01 Те Брод Инститьют, Инк. Конструирование систем, способы и оптимизированные направляющие композиции для манипуляции с последовательностями
SG11201504519TA (en) 2012-12-12 2015-07-30 Broad Inst Inc Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
AU2014214719B2 (en) 2013-02-07 2020-02-13 The General Hospital Corporation Tale transcriptional activators
AU2014243796B2 (en) 2013-03-13 2018-07-19 GeneWeave Biosciences, Inc. Non-replicative transduction particles and transduction particle-based reporter systems
HUE034987T2 (en) 2013-03-14 2018-05-02 Alnylam Pharmaceuticals Inc C5 complementary component IRNS preparations and methods for their use
CA2918194C (en) 2013-03-27 2022-12-06 The General Hospital Corporation Methods and agents for treating alzheimer's disease
CA2910489A1 (en) 2013-05-15 2014-11-20 Sangamo Biosciences, Inc. Methods and compositions for treatment of a genetic condition
PT2999785T (pt) 2013-05-22 2018-07-09 Alnylam Pharmaceuticals Inc Composições de irna de serpina1 e métodos de uso das mesmas
BR112015029276B1 (pt) 2013-05-22 2022-07-12 Alnylam Pharmaceuticals, Inc Agente de irna fita dupla capaz de inibir a expressão de tmprss6, composição farmacêutica e uso dos mesmos
AU2014272024B2 (en) 2013-05-29 2018-03-15 Vybion, Inc. Single chain intrabodies that alter huntingtin mutant degradation
WO2014204728A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
KR20160044457A (ko) 2013-06-17 2016-04-25 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 탠덤 안내 시스템, 방법 및 조성물의 전달, 조작 및 최적화
RU2716420C2 (ru) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
BR122021009076B1 (pt) 2013-06-17 2024-02-15 The Broad Institute Inc. Vetor viral contendo molécula(s) de ácido nucleico heterólogo, composição, uso e métodos do mesmo
EP3725885A1 (de) 2013-06-17 2020-10-21 The Broad Institute, Inc. Funktionale genomik unter verwendung von crispr-cas-systemen, zusammensetzungen, verfahren, schirme und anwendungen davon
KR20160034901A (ko) 2013-06-17 2016-03-30 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작에 최적화된 ｃｒｉｓｐｒ-ｃａｓ 이중 닉카아제 시스템, 방법 및 조성물
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
AU2014312295C1 (en) 2013-08-28 2020-08-13 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
EP3052626A1 (de) 2013-10-02 2016-08-10 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
UA124961C2 (uk) 2013-10-04 2021-12-22 Елнілем Фармасьютикалз, Інк. ДВОНИТКОВА РИБОНУКЛЕЇНОВА КИСЛОТА (dsRNA) ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ALAS1
US9957526B2 (en) 2013-10-17 2018-05-01 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
NZ719477A (en) 2013-11-11 2022-05-27 Sangamo Therapeutics Inc Methods and compositions for treating huntington’s disease
RS62559B1 (sr) 2013-11-13 2021-12-31 Childrens Medical Center Nukleazom posredovana regulacija eksprimiranja gena
WO2015089077A2 (en) 2013-12-09 2015-06-18 Sangamo Biosciences, Inc. Methods and compositions for genome engineering
CA2932479A1 (en) 2013-12-12 2015-06-18 The Rockefeller University Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
AU2014361826A1 (en) 2013-12-12 2016-06-23 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using particle delivery components
IL282401B (en) 2013-12-12 2022-08-01 Alnylam Pharmaceuticals Inc Complementary component irna compositions and methods for using them
WO2015086828A1 (en) 2013-12-12 2015-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and treatment of diabetic cardiomyopathy using mir-424/322
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
EP3079725B1 (de) 2013-12-12 2019-10-16 The Broad Institute, Inc. Abgabe, verwendung und therapeutische anwendungen der crispr-cas-systeme und zusammensetzungen zur genomeditierung
LT3102673T (lt) 2014-02-03 2020-08-25 Sangamo Therapeutics, Inc. Beta talasemijos gydymo būdai ir kompozicijos
EP3960860A3 (de) 2014-02-11 2022-06-08 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
AU2015231353B2 (en) 2014-03-18 2020-11-05 Sangamo Therapeutics, Inc. Methods and compositions for regulation of zinc finger protein expression
KR102380324B1 (ko) 2014-05-08 2022-03-30 상가모 테라퓨틱스, 인코포레이티드 헌팅턴병을 치료하기 위한 방법 및 조성물
TW201607559A (zh) 2014-05-12 2016-03-01 阿尼拉製藥公司 治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
AU2015264038B2 (en) 2014-05-22 2021-02-11 Alnylam Pharmaceuticals, Inc. Angiotensinogen (AGT) iRNA compositions and methods of use thereof
EP3151866B1 (de) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimäre kapside
CN106852157B (zh) 2014-06-16 2022-04-12 约翰斯·霍普金斯大学 用于使用h1启动子表达crispr向导rna的组合物和方法
KR102330593B1 (ko) 2014-07-28 2021-11-26 에스케이이노베이션 주식회사 신규 이소프렌 신타아제 및 이를 이용한 이소프렌의 제조방법
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
ES2780904T3 (es) 2014-08-17 2020-08-27 Broad Inst Inc Edición genómica usando nickasas Cas9
EP3186368B1 (de) 2014-08-25 2020-01-15 Geneweave Biosciences Inc. Nichtreplikative transduktionspartikel und auf transduktionspartikeln basierende reportersysteme
CN107073091A (zh) 2014-09-07 2017-08-18 西莱克塔生物科技公司 用于减弱外显子跳读抗病毒转移载体免疫应答的方法和组合物
HUE055583T2 (hu) 2014-09-16 2021-12-28 Sangamo Therapeutics Inc Eljárások és készítmények nukleáz által közvetített genommódosításhoz és -javításhoz hematopoetikus õssejtekben
WO2016049024A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049251A1 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
JOP20200115A1 (ar) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EP3215191A4 (de) 2014-11-05 2018-08-01 Voyager Therapeutics, Inc. Aadc-polynukleotide zur behandlung von morbus parkinson
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
JP6863891B2 (ja) 2014-11-14 2021-04-21 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 調節性ポリヌクレオチド
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
AU2015350120B2 (en) 2014-11-17 2021-05-27 Alnylam Pharmaceuticals, Inc. Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
EP3230451B1 (de) 2014-12-12 2021-04-07 The Broad Institute, Inc. Geschützte guide-rnas (pgrnas)
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
WO2016108926A1 (en) 2014-12-30 2016-07-07 The Broad Institute Inc. Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
CA2976445A1 (en) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
US20180094243A1 (en) 2015-04-03 2018-04-05 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2016201301A1 (en) 2015-06-12 2016-12-15 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2016205728A1 (en) 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Crispr mediated recording of cellular events
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
AU2016279077A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
AU2016291778B2 (en) 2015-07-13 2021-05-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3365441A1 (de) 2015-10-22 2018-08-29 The Broad Institute Inc. Crispr-enzyme des typs vi-b und systeme
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US10983110B2 (en) 2015-12-02 2021-04-20 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
CN108778297B (zh) 2015-12-18 2024-02-09 桑格摩生物治疗股份有限公司 T细胞受体的靶向破坏
WO2017106537A2 (en) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the mhc cell receptor
US20190233814A1 (en) 2015-12-18 2019-08-01 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2017109034A1 (en) 2015-12-24 2017-06-29 Oxyrane Uk Ltd Human alpha-n-acetylgalactosaminidase polypeptide
US20170202931A1 (en) 2016-01-15 2017-07-20 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease
EP3408391A4 (de) 2016-01-31 2019-08-28 University of Massachusetts Verzweigte oligonukleotide
CN109069568B (zh) 2016-02-02 2023-07-07 桑格摩生物治疗股份有限公司 用于连接dna结合结构域和切割结构域的组合物
EP3416726A4 (de) 2016-02-17 2019-08-28 Children's Medical Center Corporation Ffa1 (gpr40) als therapeutisches ziel für nervenangiogeneseerkrankungen oder funktionsstörungen
CN110382692A (zh) 2016-04-19 2019-10-25 博德研究所 新型crispr酶以及系统
AU2017257274B2 (en) 2016-04-19 2023-07-13 Massachusetts Institute Of Technology Novel CRISPR enzymes and systems
AU2017253107B2 (en) 2016-04-19 2023-07-20 Massachusetts Institute Of Technology CPF1 complexes with reduced indel activity
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (de) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
BR112018073384A2 (pt) 2016-05-18 2019-03-06 Voyager Therapeutics, Inc. polinucleotídeos moduladores
WO2017201258A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
JP2019518028A (ja) 2016-06-10 2019-06-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分Ｃ５ｉＲＮＡ組成物及び発作性夜間血色素尿症（ＰＮＨ）を処置するためのその使用方法
JP2020511931A (ja) 2016-06-16 2020-04-23 オスロ ウニヴェルスィテーツスィーケフース ハーエフＯｓｌｏ Ｕｎｉｖｅｒｓｉｔｅｔｓｓｙｋｅｈｕｓ Ｈｆ 改良された遺伝子編集
JP7267013B2 (ja) 2016-06-17 2023-05-01 ザ・ブロード・インスティテュート・インコーポレイテッド Ｖｉ型ｃｒｉｓｐｒオルソログ及び系
US20210222164A1 (en) 2016-06-29 2021-07-22 The Broad Institute, Inc. Crispr-cas systems having destabilization domain
CA3029860A1 (en) 2016-07-05 2018-01-11 The Johns Hopkins University Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter
ES2938210T3 (es) 2016-07-13 2023-04-05 Vertex Pharma Métodos, composiciones y kits para aumentar la eficiencia de edición del genoma
CA3030587A1 (en) 2016-07-15 2018-01-18 Salk Institute For Biological Studies Methods and compositions for genome editing in non-dividing cells
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
EP3500670A4 (de) 2016-08-17 2020-08-19 The Broad Institute, Inc. Neuartige crispr-enzyme und -systeme
EP3500671A4 (de) 2016-08-17 2020-07-29 The Broad Institute, Inc. Neuartige crispr-enzyme und -systeme
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
LT3504229T (lt) 2016-08-24 2021-12-10 Sangamo Therapeutics, Inc. Genų raiškos reguliavimas, panaudojant rekombinantines nukleazes
WO2018039448A1 (en) 2016-08-24 2018-03-01 Sangamo Therapeutics, Inc. Engineered target specific nucleases
EP3506817A4 (de) 2016-08-30 2020-07-22 The Regents of The University of California Verfahren für biomedizinisches targeting und freisetzung sowie vorrichtungen und systeme zur ausführung davon
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
KR20190060829A (ko) 2016-10-20 2019-06-03 상가모 테라퓨틱스, 인코포레이티드 파브리병의 치료를 위한 방법 및 조성물
WO2018081775A1 (en) 2016-10-31 2018-05-03 Sangamo Therapeutics, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
WO2018106782A1 (en) 2016-12-08 2018-06-14 Case Western Reserve University Methods and compositions for enhancing functional myelin production
KR20230166146A (ko) 2016-12-16 2023-12-06 알닐람 파마슈티칼스 인코포레이티드 트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20190130613A (ko) 2017-03-23 2019-11-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
WO2018195338A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
WO2018204786A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
US11752181B2 (en) 2017-05-05 2023-09-12 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
US20210278416A1 (en) 2017-05-09 2021-09-09 The Broad Institute, Inc. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases
CA3058848A1 (en) 2017-05-09 2018-11-15 Vib Vzw Means and methods for treating bacterial infections
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2018236548A1 (en) 2017-06-23 2018-12-27 Inscripta, Inc. NUCLEIC ACID GUIDED NUCLEASES
WO2019005884A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. CRISPR / CAS-ADENINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED NUCLEIC ACID EDITION
US11168322B2 (en) 2017-06-30 2021-11-09 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
MX2020001187A (es) 2017-08-03 2020-10-05 Voyager Therapeutics Inc Composiciones y métodos para la administración de virus adenoasociados.
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
JP2020535802A (ja) 2017-09-21 2020-12-10 ザ・ブロード・インスティテュート・インコーポレイテッド 標的化核酸編集のための系、方法、及び組成物
WO2019079240A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. USES OF BASIC EDITORS ADENOSINE
WO2019089922A1 (en) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
WO2019100039A1 (en) 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
US11008602B2 (en) 2017-12-20 2021-05-18 Roche Molecular Systems, Inc. Non-replicative transduction particles and transduction particle-based reporter systems
AU2019209293B2 (en) 2018-01-17 2023-07-27 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
EP3740479A1 (de) 2018-01-17 2020-11-25 Vertex Pharmaceuticals Incorporated Dna-pk-inhibitoren
WO2019143677A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
WO2019160383A1 (ko) 2018-02-19 2019-08-22 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
WO2019178428A1 (en) 2018-03-14 2019-09-19 Arbor Biotechnologies, Inc. Novel crispr dna and rna targeting enzymes and systems
AU2019236210A1 (en) 2018-03-14 2020-09-10 Arbor Biotechnologies, Inc. Novel CRISPR DNA targeting enzymes and systems
US20210198330A1 (en) 2018-05-23 2021-07-01 The Broad Institute, Inc. Base editors and uses thereof
KR20210089629A (ko) 2018-06-05 2021-07-16 라이프에디트 테라퓨틱스, 인크. Rna-가이드된 뉴클레아제 및 그의 활성 단편 및 변이체 및 사용 방법
US20210301288A1 (en) 2018-07-16 2021-09-30 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
WO2020033601A1 (en) 2018-08-07 2020-02-13 The Broad Institute, Inc. Novel cas12b enzymes and systems
TW202020157A (zh) 2018-08-16 2020-06-01 美商艾爾妮蘭製藥公司 用於抑制lect2基因表現之組合物及方法
US20210317429A1 (en) 2018-08-20 2021-10-14 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
JP2022500052A (ja) 2018-09-18 2022-01-04 サンガモ セラピューティクス， インコーポレイテッド プログラム細胞死１（ｐｄ１）特異的ヌクレアーゼ
EP3867375A1 (de) 2018-10-15 2021-08-25 Fondazione Telethon Genomeditierungsverfahren und konstrukte
AU2019360269A1 (en) 2018-10-18 2021-05-27 Intellia Therapeutics, Inc. Nucleic acid constructs and methods of use
US20220389395A1 (en) 2018-10-29 2022-12-08 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020102659A1 (en) 2018-11-15 2020-05-22 The Broad Institute, Inc. G-to-t base editors and uses thereof
US20220025367A1 (en) 2018-11-23 2022-01-27 Sanofi Novel rna compositions and methods for inhibiting angptl8
EP3898958A1 (de) 2018-12-17 2021-10-27 The Broad Institute, Inc. Crispr-assoziierte transposase-systeme und verfahren zu deren verwendung
CN113227404A (zh) 2018-12-27 2021-08-06 豪夫迈·罗氏有限公司 用于检测鲍氏不动杆菌的非复制型转导颗粒和基于转导颗粒的报告系统
EP4339286A2 (de) 2018-12-27 2024-03-20 LifeEDIT Therapeutics, Inc. Polypeptide zur geneditierung und verwendungsverfahren
US11572595B2 (en) 2018-12-31 2023-02-07 Roche Molecular Systems, Inc. Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
WO2020181180A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to c:g base editors and uses thereof
WO2020181178A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through thymine alkylation
WO2020181202A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to t:a base editing through adenine deamination and oxidation
US20220170013A1 (en) 2019-03-06 2022-06-02 The Broad Institute, Inc. T:a to a:t base editing through adenosine methylation
WO2020181195A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenine excision
WO2020191102A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Type vii crispr proteins and systems
KR20210143230A (ko) 2019-03-19 2021-11-26 더 브로드 인스티튜트, 인코퍼레이티드 뉴클레오티드 서열을 편집하기 위한 방법 및 조성물
KR20210154176A (ko) 2019-04-09 2021-12-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 표적화된 생체내 후성유전학적 억제에 의한 장기지속성 진통
WO2020210751A1 (en) 2019-04-12 2020-10-15 The Broad Institute, Inc. System for genome editing
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20220211741A1 (en) 2019-04-18 2022-07-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and prognosis of cancer
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
US20210317192A9 (en) 2019-05-29 2021-10-14 Massachusetts Institute Of Technology Hiv-1 specific immunogen compositions and methods of use
CA3147875A1 (en) 2019-07-19 2021-01-28 Flagship Pioneering Innovations Vi, Llc Recombinase compositions and methods of use
WO2021025750A1 (en) 2019-08-08 2021-02-11 The Broad Institute, Inc. Base editors with diversified targeting scope
EP4013864A1 (de) 2019-08-12 2022-06-22 Lifeedit Therapeutics, Inc. Rna-gesteuerte nukleasen, aktive fragmente und varianten davon und verwendungsverfahren
WO2021030666A1 (en) 2019-08-15 2021-02-18 The Broad Institute, Inc. Base editing by transglycosylation
EP4022061A1 (de) 2019-08-27 2022-07-06 Sanofi Zusammensetzungen und verfahren zur hemmung von pcsk9
US20220290152A1 (en) 2019-09-03 2022-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
EP4028514A1 (de) 2019-09-09 2022-07-20 Beam Therapeutics Inc. Neue crispr-enzyme, verfahren, systeme und verwendungen davon
JP2022547570A (ja) 2019-09-12 2022-11-14 ザ・ブロード・インスティテュート・インコーポレイテッド 操作済みのアデノ随伴ウイルスキャプシド
US20220389429A1 (en) 2019-10-04 2022-12-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing ugt1a1 gene expression
WO2021072328A1 (en) 2019-10-10 2021-04-15 The Broad Institute, Inc. Methods and compositions for prime editing rna
EP4051796A1 (de) 2019-11-01 2022-09-07 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
MX2022005692A (es) 2019-11-13 2022-06-08 Alnylam Pharmaceuticals Inc Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt).
US20230086199A1 (en) 2019-11-26 2023-03-23 The Broad Institute, Inc. Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
AU2020417760A1 (en) 2019-12-30 2022-08-04 LifeEDIT Therapeutics, Inc. RNA-guided nucleases and active fragments and variants thereof and methods of use
WO2021136752A1 (en) 2019-12-31 2021-07-08 F. Hoffmann-La Roche Ag Quantitative pcr screening of inducible prophage from bacterial isolates
WO2021155065A1 (en) 2020-01-28 2021-08-05 The Broad Institute, Inc. Base editors, compositions, and methods for modifying the mitochondrial genome
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
WO2021158921A2 (en) 2020-02-05 2021-08-12 The Broad Institute, Inc. Adenine base editors and uses thereof
US20230108687A1 (en) 2020-02-05 2023-04-06 The Broad Institute, Inc. Gene editing methods for treating spinal muscular atrophy
IL295445A (en) 2020-02-10 2022-10-01 Alnylam Pharmaceuticals Inc Preparations and methods for silencing vegf-a expression
EP4127171A2 (de) 2020-03-30 2023-02-08 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
CA3179411A1 (en) 2020-04-06 2021-10-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing myoc expression
CN116134135A (zh) 2020-04-07 2023-05-16 阿尔尼拉姆医药品有限公司 用于沉默scn9a表达的组合物和方法
TW202208626A (zh) 2020-04-24 2022-03-01 美商生命編輯公司 Rna引導核酸酶及其活性片段與變體，以及使用方法
EP4143315A1 (de) 2020-04-28 2023-03-08 The Broad Institute Inc. <smallcaps/>?ush2a? ?gezielte basisbearbeitung eines thegens
JP2023525513A (ja) 2020-05-06 2023-06-16 セレクティス ソシエテ アノニム 細胞ゲノムにおける外因性配列の標的化挿入のための方法
WO2021224416A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
CN116096873A (zh) 2020-05-08 2023-05-09 布罗德研究所股份有限公司 同时编辑靶标双链核苷酸序列的两条链的方法和组合物
WO2021231437A1 (en) 2020-05-11 2021-11-18 LifeEDIT Therapeutics, Inc. Rna-guided nucleic acid binding proteins and active fragments and variants thereof and methods of use
EP4153746A1 (de) 2020-05-21 2023-03-29 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
EP4182454A1 (de) 2020-07-15 2023-05-24 Lifeedit Therapeutics, Inc. Uracil-stabilisierende proteine und aktive fragmente sowie varianten davon und verfahren zur verwendung
WO2022034374A2 (en) 2020-08-11 2022-02-17 University Of Oslo Improved gene editing
WO2022046760A2 (en) 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
AU2021339805A1 (en) 2020-09-11 2023-05-25 LifeEDIT Therapeutics, Inc. Dna modifying enzymes and active fragments and variants thereof and methods of use
CA3197726A1 (en) 2020-10-15 2022-04-21 Simon Auslaender Nucleic acid constructs for simultaneous gene activation
AU2021360197A1 (en) 2020-10-15 2023-05-18 F. Hoffmann-La Roche Ag Nucleic acid constructs for va rna transcription
US20240035029A1 (en) 2020-10-16 2024-02-01 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
JP2023546103A (ja) 2020-10-16 2023-11-01 サノフイ Ａｎｇｐｔｌ３を阻害するための新規のｒｎａ組成物および方法
AU2021365822A1 (en) 2020-10-21 2023-06-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating primary hyperoxaluria
EP4256053A1 (de) 2020-12-01 2023-10-11 Alnylam Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur hemmung der hao1 (hydroxysäureoxidase 1 (glycolatoxidase))-genexpression
CA3173950A1 (en) 2021-03-22 2022-09-22 Tyson D. BOWEN Dna modifyng enzymes and active fragments and variants thereof and methods of use
CN117529555A (zh) 2021-03-23 2024-02-06 比姆医疗股份有限公司 新颖crispr酶、方法、系统及其用途
CA3215435A1 (en) 2021-04-16 2022-10-20 Giuseppe Ciaramella Genetic modification of hepatocytes
AU2022277649A1 (en) 2021-05-21 2023-11-30 Cellectis S.A. Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
EP4349979A1 (de) 2021-05-27 2024-04-10 Institute Of Zoology, Chinese Academy Of Sciences Manipulierte cas12i-nuklease, effektorprotein und verwendung davon
CA3173953A1 (en) 2021-06-11 2023-12-10 Tyson D. BOWEN Rna polymerase iii promoters and methods of use
WO2022261509A1 (en) 2021-06-11 2022-12-15 The Broad Institute, Inc. Improved cytosine to guanine base editors
KR20240026203A (ko) 2021-06-30 2024-02-27 알닐람 파마슈티칼스 인코포레이티드 안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물
WO2023004367A2 (en) 2021-07-20 2023-01-26 The Broad Institute, Inc. Engineered targeting compositions for endothelial cells of the central nervous system vasculature and methods of use thereof
WO2023077148A1 (en) 2021-11-01 2023-05-04 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
CN114015674A (zh) 2021-11-02 2022-02-08 辉二(上海)生物科技有限公司 新型CRISPR-Cas12i系统
WO2023114953A2 (en) 2021-12-17 2023-06-22 Beam Therapeutics Inc. Novel crispr enzymes, methods, systems and uses thereof
WO2023122764A1 (en) 2021-12-22 2023-06-29 Tome Biosciences, Inc. Co-delivery of a gene editor construct and a donor template
WO2023139557A1 (en) 2022-01-24 2023-07-27 LifeEDIT Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
WO2023196802A1 (en) 2022-04-04 2023-10-12 The Broad Institute, Inc. Cas9 variants having non-canonical pam specificities and uses thereof
WO2023196772A1 (en) 2022-04-04 2023-10-12 Beam Therapeutics Inc. Novel rna base editing compositions, systems, methods and uses thereof
WO2023198685A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Method for determining aav genomes
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
WO2023215831A1 (en) 2022-05-04 2023-11-09 Tome Biosciences, Inc. Guide rna compositions for programmable gene insertion
WO2023220693A1 (en) 2022-05-12 2023-11-16 SunVax mRNA Therapeutics Inc. Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
WO2023225564A1 (en) 2022-05-18 2023-11-23 The Broad Institute, Inc. Engineered viral capsids with increased stability and methods of use thereof
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
WO2023227438A1 (en) 2022-05-23 2023-11-30 F. Hoffmann-La Roche Ag Raman-based method for the differentiation of aav particle serotype and aav particle loading status
WO2023230613A1 (en) 2022-05-27 2023-11-30 The Broad Institute, Inc. Improved mitochondrial base editors and methods for editing mitochondrial dna
WO2023232922A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2023240137A1 (en) 2022-06-08 2023-12-14 The Board Institute, Inc. Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
WO2024003334A1 (en) 2022-06-30 2024-01-04 Cellectis S.A. Enhancing safety of t-cell-mediated immunotherapy
WO2024016003A2 (en) 2022-07-14 2024-01-18 The Broad Institute, Inc. Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor
WO2024013239A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2024033901A1 (en) 2022-08-12 2024-02-15 LifeEDIT Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
WO2024040083A1 (en) 2022-08-16 2024-02-22 The Broad Institute, Inc. Evolved cytosine deaminases and methods of editing dna using same
WO2024042489A1 (en) 2022-08-25 2024-02-29 LifeEDIT Therapeutics, Inc. Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
WO2024056561A1 (en) 2022-09-12 2024-03-21 F. Hoffmann-La Roche Ag Method for separating full and empty aav particles
WO2024059791A1 (en) 2022-09-16 2024-03-21 Beam Therapeutics Inc. Large serine recombinases, systems and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) * 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter

Also Published As

Publication number Publication date
ES2168096T3 (es) 2002-06-01
EP1164195A2 (de) 2001-12-19
PT644944E (pt) 2002-05-31
CA2136441C (en) 2007-04-24
EP0644944A1 (de) 1995-03-29
CA2136441A1 (en) 1993-12-09
US6165781A (en) 2000-12-26
DE69331194D1 (de) 2002-01-03
HK1014549A1 (en) 1999-09-30
EP0644944B1 (de) 2001-11-21
US5866696A (en) 1999-02-02
US5989540A (en) 1999-11-23
DK0644944T3 (da) 2002-05-13
US5587308A (en) 1996-12-24
WO1993024641A3 (en) 1994-05-11
DE69331194T2 (de) 2002-07-25
EP1164195B1 (de) 2010-10-06
AU4598193A (en) 1993-12-30
AU673367B2 (en) 1996-11-07
ATE209254T1 (de) 2001-12-15
EP1164195A3 (de) 2005-11-23
ATE483817T1 (de) 2010-10-15
US5990279A (en) 1999-11-23
WO1993024641A2 (en) 1993-12-09

Similar Documents

Publication Publication Date Title
DE69334343D1 (de) Adeno-assoziiertes Virus mit invertierten Terminalen &#39;Repeats&#39; als Promoter
DE3786321D1 (de) Expression von protein-c.
PT728214E (pt) Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
EP1798239A3 (de) G-Protein-gekoppelte Rezeptoren und deren Verwendung
DK42887D0 (da) Fremgangsmaade til fremstilling af et proteinkompleks med human faktor viii:c aktivitet ved rekombinant-teknik
ATE88501T1 (de) Rekombinante dns-expressionsvektoren.
ES2124532T3 (es) Sistema vector-huesped utilizable en terapia genica.
ATE366814T1 (de) Gl50 moleküle, sowie verwendungen derselben
CY1107629T1 (el) Πρωτεïνη crsp (πλουσιες σε κυστεïνη εκκρινομενες πρωτεïνες) μορια νουκλεϊνικου οξεως που τις κωδικοποιουν και χρησεις τους
DE3688900T2 (de) Expression von Protein C.
EP1009752A4 (de) Neue moleküle aus der familieder tango-77-ähnlichen proteine und ihre verewendungen.
DK0988391T3 (da) Rekombinante adenovirusvektorer der omfatter en splejsningssekvens
NZ332897A (en) Methods and compositions for modulating production of a T helper type 2 (Th2)-associated cytokine by regulating transcription factor activity in association with a Nuclear Factor of Activated T cells (NF-AT) protein
EA200000202A1 (ru) Рекомбинантная экспрессия c-пептида инсулина
KR880701285A (ko) Aids 비루스의 f단백질을 함유하는 백신
DE69121118D1 (de) Genexpression in Hefezellen
DE3752281T2 (de) Stabilisierung von messenger-rns in tierischen zellen
WO2003087125A3 (en) A novel g protein-coupled purinergic receptor, gave 17